The global critical illness insurance market size is calculated at USD 385.50 billion in 2024, grew to USD 414.41 billion in 2025, and is predicted to hit around USD 854.11 billion by 2034, poised to grow at a CAGR of 7.5% between 2024 and 2034. The North America critical illness insurance market size accounted for USD 149.19 billion in 2024 and is anticipated to grow at the fastest CAGR of 7.64% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Critical Illness Insurance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Critical Illness Insurance Market, by Premium Type, 2024-2034
8.1.1 Monthly
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Quarterly
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Half Yearly
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Yearly
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Critical Illness Insurance Market, by Diseases, 2024-2034
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Heart Attack
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Stroke
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Major Organ Transplant
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Critical Illness Insurance Market, by Type, 2024-2034
10.1.1. Individual Insurance
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Family Insurance
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.1.3. Market Revenue and Forecast, by Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.2.3. Market Revenue and Forecast, by Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.3.3. Market Revenue and Forecast, by Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.5.3. Market Revenue and Forecast, by Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Premium Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Diseases (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Type (2021-2034)
12.1. AIA Group Limited
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Manulife Financial Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Prudential Financial, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Ping An Insurance (Group) Company of China, Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. China Life Insurance Company Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Allianz SE
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Zurich Insurance Group
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Aviva plc
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bupa
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. MetLife, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample